Protalix BioTherapeutics Files 8-K
Ticker: PLX · Form: 8-K · Filed: Dec 23, 2024 · CIK: 1006281
| Field | Detail |
|---|---|
| Company | Protalix Biotherapeutics, Inc. (PLX) |
| Form Type | 8-K |
| Filed Date | Dec 23, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-filing, regulation-fd
Related Tickers: PLX
TL;DR
PLX filed an 8-K on 12/23/24 with corporate details and exhibits.
AI Summary
Protalix BioTherapeutics, Inc. filed an 8-K on December 23, 2024, reporting information under Regulation FD and including financial statements and exhibits. The filing details the company's corporate structure, including its state of incorporation (Delaware) and IRS Employer Identification Number. It also lists its business and mailing addresses in Hackensack, NJ.
Why It Matters
This 8-K filing provides essential corporate and regulatory information for Protalix BioTherapeutics, Inc., impacting investors' understanding of its structure and compliance.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not contain significant new financial or operational information that would immediately impact risk.
Key Players & Entities
- Protalix BioTherapeutics, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of incorporation
- 65-0643773 (identifier) — IRS Employer Identification No.
- 2 University Plaza, Suite 100, Hackensack, NJ 07601 (address) — Business and Mailing Address
- December 23, 2024 (date) — Date of Report
FAQ
What is the primary purpose of this 8-K filing for Protalix BioTherapeutics, Inc.?
The primary purpose is to report information under Regulation FD and to include financial statements and exhibits, as indicated by the filing's item information.
When was this 8-K report filed?
The report was filed on December 23, 2024.
In which U.S. state is Protalix BioTherapeutics, Inc. incorporated?
Protalix BioTherapeutics, Inc. is incorporated in Delaware.
What is the company's IRS Employer Identification Number?
The company's IRS Employer Identification Number is 65-0643773.
Where are Protalix BioTherapeutics, Inc.'s business and mailing addresses located?
The company's business and mailing addresses are located at 2 University Plaza, Suite 100, Hackensack, NJ 07601.
Filing Stats: 518 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2024-12-23 07:01:23
Key Financial Figures
- $0.001 — ange on which registered Common stock, $0.001 par value PLX NYSE American Indic
Filing Documents
- plx-20241223x8k.htm (8-K) — 39KB
- plx-20241223xex99d1.htm (EX-99.1) — 21KB
- plx-20241223xex99d1001.jpg (GRAPHIC) — 5KB
- 0001558370-24-016445.txt ( ) — 194KB
- plx-20241223.xsd (EX-101.SCH) — 3KB
- plx-20241223_lab.xml (EX-101.LAB) — 16KB
- plx-20241223_pre.xml (EX-101.PRE) — 11KB
- plx-20241223x8k_htm.xml (XML) — 5KB
01
Item 7.01 Regulation FD Disclosure On December 23, 2024, Protalix BioTherapeutics, Inc. issued a press release containing a copy of a letter that the Company released to its stockholders. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under either the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits Exhibit No. Description 99.1 Press Release dated December 23, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 23, 2024 PROTALIX BIOTHERAPEUTICS, INC. By: /s/ Dror Bashan Name: Dror Bashan Title: President and Chief Executive Officer